放射性碘难治性分化型甲状腺癌去分化分子机制及再分化治疗的分子靶向药物  

Molecular mechanism of dedifferentiation and molecular targeted drugs for redifferentiation therapy of radioiodine refractory differentiated thyroid cancer

作　　者：刘建宇 朱宗平[1] 石德道[1] 郑飞波[1] Liu Jianyu;Zhu Zongping;Shi Dedao;Zheng Feibo(Department of Nuclear Medicine,Qingdao Municipal Hospital,Qingdao 266071,China)

机构地区：[1]青岛市市立医院核医学科,青岛266071

出　　处：《国际放射医学核医学杂志》2023年第2期123-126,共4页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：甲状腺癌是最常见的内分泌肿瘤,其中分化型甲状腺癌(DTC)占90%以上。DTC患者预后良好,但仍有局部复发和远处转移的风险。多数DTC患者的肿瘤细胞基底膜中钠/碘同向转运体表达障碍,导致肿瘤细胞摄碘能力降低,最终进展为放射性碘难治性DTC(RAIR-DTC),此类患者预后较差。笔者就DTC失分化的相关基因及当前文献报道的可逆转RAIR-DTC细胞摄碘能力的分子靶向药物进行综述。Thyroid cancer is the most common endocrine tumor,of which differentiated thyroid cancer(DTC)accounts for more than 90%.The prognosis of patients with DTC is good,but there is still a risk of local recurrence and distant metastasis.The expression of sodium/iodine symporter in the basement membrane of tumor cells in most DTC patients is impaired,which led to the iodine uptake capacity of tumor cell is decreased,and the final progression is radioiodine refractory DTC(RAIR-DTC).The prognosis of these patients is poor.This paper reviews the genes related to DTC dedifferentiation and the molecular targeted drugs that can reverse RAIR-DTC cell iodine uptake reported in the literature.

关 键 词：甲状腺肿瘤 碘放射性同位素 细胞去分化 分子靶向治疗 基因 

分 类 号：R736.1[医药卫生—肿瘤]